FY2025 · ended Dec 31, 2025 · Revenue $81.36M, +14.9% YoY · Filed Mar 10, 2026
ADC Therapeutics SA (ADCT) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $81.4 million and a net loss of $142.6 million. Free cash flow was -$141.4 million. As of Jun 30, 2026 it held $219.1 million in cash and investments and $7.1 million in total debt.
Revenue (TTM)
$84.53M
+18.3% vs year-ago TTM
Net income (TTM)
$-96.91M
+43.0% vs year-ago TTM
Operating cash flow (TTM)
$-102.27M
+19.7% vs year-ago TTM
Free cash flow (TTM)
$-102.30M
+20.0% vs year-ago TTM
EPS (TTM)
$-0.65
+58.7% vs year-ago TTM
Dividend per share
None
Shares outstanding
127.04M
+28.2% vs prior year
Net cash
$211.98M
as of Jun 30, 2026
Operating margin
-117.8%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ADCT (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- Switzerland
- Headquarters
- Epalinges, Switzerland
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1771910
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $81.4M | $70.8M | $69.6M | $209.9M | $33.9M |
| Operating income | -$121.5M | -$130.7M | -$166.0M | — | — |
| Net income | -$142.6M | -$157.8M | -$240.1M | — | — |
| Diluted EPS | -$1.12 | -$1.62 | -$2.94 | — | — |
| Operating cash flow | -$141.2M | -$123.8M | -$118.7M | -$136.8M | -$233.4M |
| Free cash flow | -$141.4M | -$124.7M | -$121.9M | -$137.4M | -$236.8M |
| Total assets | $323.1M | $322.0M | $354.8M | $490.9M | $618.0M |
| Total liabilities | $509.0M | $524.6M | $503.0M | $411.4M | $451.9M |
| Stockholders' equity | -$185.8M | -$202.6M | -$148.2M | — | — |
| Cash and investments | $261.3M | $250.9M | $278.6M | $326.4M | $466.5M |
| Total debt | $4.6M | $9.4M | $11.6M | $7.7M | $95.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations, Regulation FD disclosure, Other events
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Material agreement, Results of operations, Unregistered share sale
|
Oct 13, 2026 | Oct 7, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 13, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 2, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 24, 2026 | Jun 24, 2026 |
All 438 ADC Therapeutics SA SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.